MedTech News
AliveCor Announces Dual FDA Clearance of AI Technology That Delivers 35 Cardiac Determinations and First-of-its-Kind Kardia 12L ECG System
Powered by this AI, the Pocket-Sized Kardia 12L ECG System Enables Faster, Easier Detection of Life-Threatening Cardiac Conditions
Novel blood-powered chip offers real-time health monitoring
Researchers at the University of Pittsburgh and University of Pittsburgh Medical Center are proposing a new device that uses blood to generate electricity and measure its conductivity, opening doors to medical care in any location.
FDA approves Endotronix Cordella PA sensor system for heart failure treatment
Endotronix today announced it received FDA premarket approval for its Cordella PA Sensor System.
Axogen launches Avive+ Soft Tissue Matrix
Axogen (Nasdaq:AXGN) today announced it has launched its Avive+ Soft Tissue Matrix.
Philips launches Duo Venous Stent System for treatment of symptomatic venous outflow obstruction
Philips, a global leader in health technology, has announced the first implant of the Duo Venous Stent System, an implantable medical device indicated to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency (CVI), following premarket approval (PMA) from the U.S. Food and Drug Administration (FDA).
FDA clears orthopedics robot for TKA from Globus Medical
Globus Medical has won FDA clearance for its new ExcelsiusFlex orthopedics robot stereotaxic surgery in knee procedures and an expanded indication for its ExcelsiusHub system.
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products.
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.